Aerovate Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Aerovate Therapeutics Inc
TickerJBIO
CIK #0001798749
CUSIP008064206
SectorLife Sciences - Pharmaceutical Preparations
Address200 Berkeley Street Floor 18, Boston, MA 02116
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Aerovate Therapeutics Inc 2020-08-14 75.8 M Exemption: 506(b) · Duration: One year or less · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001798749] 10-K
[0001798749] 10-Q
[0001798749] 3
[0001798749] 4
[0001798749] 8-K
[0001798749] D
[0001798749] SC 13D
[0001798749] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Paradigm Biocapital Advisors LP Jade Biosciences Inc [2026-07-17] 0.0
Bellevue Group AG Jade Biosciences Inc [2026-02-17] 0.0
Janus Henderson Group PLC Jade Biosciences Inc [2026-02-17] 0.0
RA Capital Management LP Jade Biosciences Inc [2025-10-16] 0.0
Vanguard Group Inc Jade Biosciences Inc [2025-07-29] 0.0
BlackRock Inc Jade Biosciences Inc [2025-07-17] 0.0
Deep Track Capital LP Jade Biosciences Inc [2025-06-20] 0.0
FMR LLC Jade Biosciences Inc [2025-06-06] 0.0
Venrock Healthcare Capital Partners III LP Jade Biosciences Inc [2025-05-05] 0.0
Frazier Life Sciences Public Fund LP Jade Biosciences Inc [2025-05-05] 0.0
Fairmount Funds Management LLC Jade Biosciences Inc [2025-05-01] 0.0
TCG Crossover GP I LLC Aerovate Therapeutics Inc [2024-02-09] 8.0
Baker Bros Advisors LP Aerovate Therapeutics Inc [2022-02-14] 7.5
Atlas Venture Associates XII LLC Aerovate Therapeutics Inc [2021-11-05] 12.7
Sofinnova Venture Partners X LP Aerovate Therapeutics Inc [2021-07-13] 11.0
Citadel Advisors LLC Aerovate Therapeutics Inc [2021-07-12] 6.6
RA Capital Management LP Aerovate Therapeutics Inc [2021-07-12] 33.9
Cormorant Asset Management LP Aerovate Therapeutics Inc [2021-07-12] 3.36
Form 3/4/5 Filer 2011 - 2026
Jade Biosciences Inc
Eisner Mark
Lavelle Erin
Cain Christopher W
Dobmeier Eric
Klein Lawrence Otto
Kiselak Tomas
Fairmount Funds Management LLC
Harwin Peter Evan
Fairmount Healthcare Fund II LP
Fairmount Healthcare Co-Invest IV LP
Frohlich Tom
King Andrew James
Dahms Bradford D
Balta Elizabeth
Quick Jonathan
Kocinsky Hetal
Shah Rajeev M
RA Capital Healthcare Fund LP
RA Capital Management LP
Kolchinsky Peter
Dake Benjamin T
RA Capital Nexus Fund LP
Gillies Hunter
Eldridge George A
Verwijs Marinus
Dable Habib J
Dorval Allison
Iwicki Mark T
Katabi Maha
Resnick Joshua
Santel Donald J
Grayzel David S
Noyes Timothy P
Niven Ralph
Pigot Timothy
Atlas Venture Fund XII LP
Cormorant Private Healthcare Fund II LP
Cormorant Global Healthcare Master Fund LP
Chen Bihua
Cormorant Asset Management LP
Sofinnova Venture Partners X LP
Sofinnova Management X LP
Healy James
Atlas Venture Associates XII LP
Atlas Venture Associates XII LLC
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Balta Elizabeth
Common Stock
2026-02-12 Grant 28,125 $0.00
Dahms Bradford D
Common Stock
2026-02-12 Grant 37,813 $0.00
King Andrew James
Stock Option (Right to Buy) · derivative
2026-02-12 Grant 247,500 $0.00
Dahms Bradford D
Stock Option (Right to Buy) · derivative
2026-02-12 Grant 226,875 $0.00
Balta Elizabeth
Stock Option (Right to Buy) · derivative
2026-02-12 Grant 168,750 $0.00
Frohlich Tom
Common Stock
2026-02-12 Grant 78,750 $0.00
Frohlich Tom
Stock Option (Right to Buy) · derivative
2026-02-12 Grant 472,500 $0.00
King Andrew James
Common Stock
2026-02-12 Grant 41,250 $0.00
Kiselak Tomas +4
Common Stock
2025-10-06 Grant 1,333,126 $9.14 12,184,772
Kiselak Tomas +4
Pre-Funded Warrant (Right to Buy) · derivative
2025-10-06 Grant 855,047 $9.14 7,815,130
Dahms Bradford D
Stock Option (Right to Buy) · derivative
2025-07-14 Grant 526,000 $0.00
Frohlich Tom
Common Stock
2025-05-16 Buy 6,000 $7.40 44,400
Lavelle Erin
Stock Option (Right to Buy) · derivative
2025-04-29 Grant 23,017 $0.00
Klein Lawrence Otto
Stock Option (Right to Buy) · derivative
2025-04-29 Grant 23,017 $0.00
Cain Christopher W
Stock Option (Right to Buy) · derivative
2025-04-29 Grant 23,017 $0.00
Dobmeier Eric
Stock Option (Right to Buy) · derivative
2025-04-29 Grant 23,017 $0.00
Kiselak Tomas +3
Stock Option (Right to Buy) · derivative
2025-04-29 Grant 23,017 $0.00
Shah Rajeev M +3
Common Stock
2025-04-28 Other 1,062,326
Dake Benjamin T
Stock Option (Right to Buy) · derivative
2024-08-01 Option exercise 1,507 $0.00
Dake Benjamin T
Common Stock
2024-08-01 Option exercise 1,507 $1.74 2,622
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 122 51,458,099
2025-12-31 107 47,170,869
2025-09-30 79 31,688,916
2025-06-30 74 31,593,490
Form 13F Holdings
Firm Period DFND Voting Shares
Gamma Investing LLC [2026-06-30] DFND 916 916
Versant Capital Management Inc [2026-06-30] SOLE 905 905
Farther Finance Advisors LLC [2026-06-30] SOLE 0 66
Fortitude Family Office LLC [2026-06-30] SOLE 29 29
Ares Financial Consulting LLC [2026-06-30] SOLE 20 20
Owl Creek Wealth Partners LLC [2026-06-30] SOLE 0 7
Capital Advisors Ltd LLC [2026-06-30] SOLE 0 6
IFP Advisors LLC [2026-06-30] SOLE 6 6
Hughes Financial Services LLC [2026-06-30] SOLE 2 2
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com